European Leukemia Trial Registry
Trial: CP4055-205

More Details
Title Elacytarabine (CP-4055) Plus Idarubicin as second-line treatment in AML
Scientific Title A Phase II Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Short Title CP4055-205
Trialgroup NN
Type of Trial single-group, open-label
Disease Acute myeloid leukemia(AML) AML all subtypes without FAB M3
Age >= 18 years
Status No longer recruiting
Start of Recruitment 15.12.2009
Shortprotocol Shortprotocol
Remark contacts see: http://clinicaltrials.gov/ct2/show/record/NCT01035502
created 16.07.2010 Johannes Kraus
changed 08.06.2015 Hanna Ebert
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org